Literature DB >> 32727888

Insights into the Mechanism of Action of Highly Diluted Biologics.

Sergey A Tarasov1,2, Evgeniy A Gorbunov3, Elena S Don1,2, Alexandra G Emelyanova1,2, Alexander L Kovalchuk1, Naveena Yanamala4, A Sylvia S Schleker4, Judith Klein-Seetharaman4, Reno Groenestein5, Jean-Pierre Tafani6, Peter van der Meide5, Oleg I Epstein1,2.   

Abstract

The therapeutic use of Abs in cancer, autoimmunity, transplantation, and other fields is among the major biopharmaceutical advances of the 20th century. Broader use of Ab-based drugs is constrained because of their high production costs and frequent side effects. One promising approach to overcome these limitations is the use of highly diluted Abs, which are produced by gradual reduction of an Ab concentration to an extremely low level. This technology was used to create a group of drugs for the treatment of various diseases, depending on the specificity of the used Abs. Highly diluted Abs to IFN-γ (hd-anti-IFN-γ) have been demonstrated to be efficacious against influenza and other respiratory infections in a variety of preclinical and clinical studies. In the current study, we provide evidence for a possible mechanism of action of hd-anti-IFN-γ. Using high-resolution solution nuclear magnetic resonance spectroscopy, we show that the drug induced conformational changes in the IFN-γ molecule. Chemical shift changes occurred in the amino acids located primarily at the dimer interface and at the C-terminal region of IFN-γ. These molecular changes could be crucial for the function of the protein, as evidenced by an observed hd-anti-IFN-γ-induced increase in the specific binding of IFN-γ to its receptor in U937 cells, enhanced induced production of IFN-γ in human PBMC culture, and increased survival of influenza A-infected mice.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 32727888     DOI: 10.4049/jimmunol.2000098

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Highly Diluted Antibodies to eNOS Restore Endothelium Function in Aortic Rings From Hypertensive Rats.

Authors:  Nataliya V Petrova; Sergey A Tarasov; Oleg I Epstein; Caroline Dubroca; Thierry Sulpice
Journal:  Dose Response       Date:  2022-05-17       Impact factor: 2.623

2.  Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial.

Authors:  Sergey N Avdeev; Alexander A Vizel; Vladimir N Abrosimov; Andrey A Zaicev; Galina L Ignatova; Rustem F Khamitov; Marina P Mikhaylusova; Julia S Shapovalova; Elena F Pavlysh; Basil I Trofimov; Alexander V Emelyanov; Tatiana I Martynenko; Vladimir A Martynenko; Natalia E Kostina; Danila A Chizhov; Olga Yu Chizhova; Natalia A Kuzubova; Elena V Makova; Ekaterina V Makarova
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-05-05

3.  Efficacy and Safety of Ergoferon in Children from 6 Months to 6 Years Old with Acute Respiratory Viral Infections in Contemporary Outpatient Practice: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial.

Authors:  N A Geppe; B M Blokhin; O V Shamsheva; S T Abdrakhmanova; K A Alikhanova; G T Myrzabekova
Journal:  Can Respir J       Date:  2021-11-15       Impact factor: 2.409

4.  The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders.

Authors:  Vladimir Anatolevich Parfenov; Pavel Rudolfovich Kamchatnov; Dina Rustemovna Khasanova; Enver Ibragimovich Bogdanov; Tatiana Markovna Lokshtanova; Aleksandr Vitalevich Amelin; Natalya Nikolaevna Maslova; Nataliia Vyacheslavovna Pizova; Galina Nikolaevna Belskaya; Evgeny Robertovich Barantsevich; Gulsum Abdurahmanovna Duchshanova; Saltanat Ualihanovna Kamenova; Oleg Vladimirovich Kolokolov; Alexey Borisovich Glazunov
Journal:  Sci Rep       Date:  2021-12-20       Impact factor: 4.996

5.  New insights into the microscopic interactions associated with the physical mechanism of action of highly diluted biologics.

Authors:  Kristina N Woods
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

6.  IVIG ameliorate inflammation in collagen-induced arthritis: projection for IVIG therapy in rheumatoid arthritis.

Authors:  G Halpert; I Katz; M Blank; O Shovman; S Tarasov; K K Ganina; N Petrova; M Tocut; A Volkov; I Barshack; H Amital
Journal:  Clin Exp Immunol       Date:  2020-10-26       Impact factor: 5.732

7.  Optical Properties of Crystalline Lactose Fluidized with Dilutions of Various Substances in the Terahertz Frequency Range.

Authors:  Anna Baranova; Anastasiya Lykina; Daria Antonova; Olga Smolyanskaya
Journal:  Pharmaceutics       Date:  2021-12-24       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.